| 1 |
Tutunchi H, Arefhosseini S, Ebrahimi-Mameghani M. Clinical effectiveness of α-lipoic acid, myo-inositol and propolis supplementation on metabolic profiles and liver function in obese patients with NAFLD: A randomized controlled clinical trial. Clin Nutr ESPEN 2023;54:412-20. [PMID: 36963888 DOI: 10.1016/j.clnesp.2023.02.016] [Reference Citation Analysis]
|
| 2 |
Gulzar F, Ahmad S, Singh S, Kumar P, Sharma A, Tamrakar AK. NOD1 activation in 3T3-L1 adipocytes confers lipid accumulation in HepG2 cells. Life Sci 2023;316:121400. [PMID: 36657640 DOI: 10.1016/j.lfs.2023.121400] [Reference Citation Analysis]
|
| 3 |
Zyśk B, Ostrowska L, Smarkusz-Zarzecka J, Witczak-Sawczuk K, Gornowicz A, Bielawska A. Pro-Inflammatory Adipokine and Cytokine Profiles in the Saliva of Obese Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)-A Pilot Study. Int J Mol Sci 2023;24. [PMID: 36769216 DOI: 10.3390/ijms24032891] [Reference Citation Analysis]
|
| 4 |
He Y, Su Y, Duan C, Wang S, He W, Zhang Y, An X, He M. Emerging role of aging in the progression of NAFLD to HCC. Ageing Res Rev 2023;84:101833. [PMID: 36565959 DOI: 10.1016/j.arr.2022.101833] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 5 |
Lutsiv T, McGinley JN, Neil ES, Foster MT, Thompson HJ. Thwarting Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) with Common Bean: Dose- and Sex-Dependent Protection against Hepatic Steatosis. Nutrients 2023;15. [PMID: 36771233 DOI: 10.3390/nu15030526] [Reference Citation Analysis]
|
| 6 |
Zhou T, Cao L, Qin L, Lu Y, He Y, Tan D. Differential effects of medium- and long-term high-fat diets on the expression of genes or proteins related to nonalcoholic fatty liver disease in mice. Food Sci Technol 2023;43. [DOI: 10.1590/fst.117522] [Reference Citation Analysis]
|
| 7 |
Tan X, Huang X, Lu Z, Chen L, Hu J, Tian X, Qiu Z. The essential effect of mTORC1-dependent lipophagy in non-alcoholic fatty liver disease. Front Pharmacol 2023;14:1124003. [PMID: 36969837 DOI: 10.3389/fphar.2023.1124003] [Reference Citation Analysis]
|
| 8 |
孙 田. Correlation between PNPLA3 rs3747207 Polymorphism and Non-Alcoholic Fatty Liver Disease. ACM 2023;13:1974-1981. [DOI: 10.12677/acm.2023.132274] [Reference Citation Analysis]
|
| 9 |
Cao Y, Du Y, Jia W, Ding J, Yuan J, Zhang H, Zhang X, Tao K, Yang Z. Identification of biomarkers for the diagnosis of chronic kidney disease (CKD) with non-alcoholic fatty liver disease (NAFLD) by bioinformatics analysis and machine learning. Front Endocrinol (Lausanne) 2023;14:1125829. [PMID: 36923221 DOI: 10.3389/fendo.2023.1125829] [Reference Citation Analysis]
|
| 10 |
Guo Z, Chen H, Zao X, Du H, Guo Y, Jin Q, Kong D, Liu R, Zhang T, Yun Z, Zhang J, Li X, Ye Y. Association between leptin and NAFLD: A Two-Sample Mendelian randomization study.. [DOI: 10.21203/rs.3.rs-2141400/v1] [Reference Citation Analysis]
|
| 11 |
Lu L, Xiong Y, Lin Z, Chu X, Panayi AC, Hu Y, Zhou J, Mi B, Liu G. Advances in the therapeutic application and pharmacological properties of kinsenoside against inflammation and oxidative stress-induced disorders. Front Pharmacol 2022;13:1009550. [DOI: 10.3389/fphar.2022.1009550] [Reference Citation Analysis]
|
| 12 |
Kosmalski M, Drzewoski J, Szymczak-pajor I, Zieleniak A, Mikołajczyk-solińska M, Kasznicki J, Śliwińska A. Irisin Is Related to Non-Alcoholic Fatty Liver Disease (NAFLD). Biomedicines 2022;10:2253. [DOI: 10.3390/biomedicines10092253] [Reference Citation Analysis]
|
| 13 |
Ismaiel A, Ciobanu OS, Ismaiel M, Leucuta D, Popa S, David L, Ensar D, Al Srouji N, Dumitrascu DL. Atherogenic Index of Plasma in Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis. Biomedicines 2022;10:2101. [DOI: 10.3390/biomedicines10092101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
